Biogen Pharmachem Industries Ltd - 531752 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Rama Shiva Lease Finance Private Limited disposed of 5.26% stake in Biogen Pharmachem on May 18, 2026. This reduces their total holding from 9.31% to 4.04% through an open market transaction.
May 20 2026 10:05:00
Biogen Pharmachem Industries Ltd - 531752 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
RAMA SHIVA LEASE FINANCE PRIVATE LIMITED disposed of 5.26% stake in Biogen Pharmachem through an open market transaction. This reduces their holding from 9.31% to 4.04%, signaling a significant reduction by a major shareholder.
May 20 2026 10:05:00
Biogen Pharmachem Industries Ltd - 531752 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Parichay Infrastructure Limited sold 3.99 crore shares of Biogen Pharmachem, decreasing its shareholding from 9.08% to 4.66%. This transaction was executed through an open market sale on May 18, 2026.
May 20 2026 09:05:00
Biogen Pharmachem Industries Ltd - 531752 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Interface Financial Services Limited sold 4.47% stake in Biogen Pharmachem, reducing its total shareholding from 9.31% to 4.84%. The transaction was executed via an open market sale.
May 19 2026 17:05:00
Biogen Pharmachem Industries Ltd - 531752 - Announcement under Regulation 30 (LODR)-Allotment
Biogen Pharmachem allotted 15.04 crore bonus equity shares, increasing its paid-up and issued capital from Rs. 90.26 crore to Rs. 105.30 crore. The shares were credited to shareholder accounts on May 18, 2026.
May 18 2026 17:05:00
Biogen Pharmachem Industries Ltd - 531752 - Board Meeting Outcome for Audited Financial Results Of The Company For The Quarter And Year Ended On 31St March, 2026 And Outcome Of The Board Meeting Held On Thursday 14Th May 2026.
Biogen Pharmachem's board approved audited FY26 financial results, with revenue at ₹255.80 lacs and a net profit of ₹85.95 lacs. This marks a substantial turnaround, with revenue growing 205% YoY and the company moving from a net loss to profitability, as confirmed by an unmodified audit opinion.
May 14 2026 16:05:00
Biogen Pharmachem Industries Ltd - 531752 - Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI (LODR) Regulations, 2015 - Intimation Of Board Meeting.
Biogen Pharmachem's Board of Directors will meet on May 14, 2026. The primary agenda is to consider and approve the audited standalone financial results for the quarter and year ended March 31, 2026.
May 04 2026 17:05:00
Biogen Pharmachem Industries Ltd - 531752 - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Biogen Pharmachem shareholders approved a 1:6 bonus equity share issue. They also approved an increase in authorized share capital and the appointment of M/s. Goenka Mehta & Associates as statutory auditors, with all resolutions passing with over 99% votes.
Apr 27 2026 17:04:00
Biogen Pharmachem Industries Ltd - 531752 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Biogen Pharmachem shareholders approved a 1:6 bonus equity share issue. They also approved an increase in authorized share capital and the appointment of M/s. Goenka Mehta & Associates as statutory auditors, with all resolutions passing with over 99% votes.
Apr 27 2026 17:04:00
Read More